In short
This article discusses the ongoing clinical trials of Pal1-15 Acetate, also known as ACI-24.060, a potential treatment for Alzheimer's disease and adults with Down syndrome. The study aims to assess the safety, tolerability, and effectiveness of this new drug in patients with early-stage Alzheimer's disease and adults with Down syndrome who have amyloid pathology in their brains.
At a glance
- Drug Name
- Pal1-15 Acetate (ACI-24.060)
- Study Type
- Phase 1b/2, multicenter, adaptive, double-blind, randomized, placebo-controlled
- Target Conditions
- Prodromal Alzheimer's disease and adults with Down syndrome
- Main Objectives
- Assess safety, tolerability, immunogenicity, and pharmacodynamic effects
- Study Duration
- Part 1: 48 weeks, Part 2: 74 weeks
- Key Assessments
- Safety monitoring, anti-Aβ antibody response, amyloid-related biomarkers, brain amyloid levels (PET scan)
- Participant Criteria
- Confirmed amyloid pathology, age-specific requirements for each part
- Study Design
- Multiple cohorts with different dosing regimens, 3:1 active treatment to placebo ratio
What is ACI-24.060?
ACI-24.060 is a new medication being studied for the treatment of Alzheimer's disease and adults with Down syndrome who are at risk of developing Alzheimer's disease. The active substance in this medication is called PAL1-15 ACETATE, which is a type of protein. It is given as an injection, typically into a muscle (intramuscular injection).
How does ACI-24.060 work?
ACI-24.060 is designed to work by targeting amyloid beta (Aβ), a protein that builds up in the brains of people with Alzheimer's disease. The medication aims to stimulate the body's immune system to produce antibodies against amyloid beta. These antibodies may help to reduce the amount of amyloid in the brain, which could potentially slow down the progression of Alzheimer's disease.
Who is the treatment for?
The clinical trial for ACI-24.060 is studying two main groups of people:
- People with early (prodromal) Alzheimer's disease, aged between 50 and 85 years old.
- Adults with Down syndrome, aged between 35 and 50 years old, who have evidence of amyloid buildup in their brains.
People with Down syndrome are included in this study because they have a higher risk of developing Alzheimer's disease at a younger age than the general population.
Clinical Trial Details
The clinical trial for ACI-24.060 is divided into two parts:
- Part 1: This part of the study focuses on people with early Alzheimer's disease. It will include up to 88 participants (or up to 112 if needed) who will receive either ACI-24.060 or a placebo (a substance with no active medication) for 48 weeks.
- Part 2: This part of the study involves adults with Down syndrome. It will include up to 88 participants who will receive either ACI-24.060 or a placebo for 74 weeks.
The study is "double-blind," which means that neither the participants nor the researchers know who is receiving the actual medication and who is receiving the placebo. This helps to ensure that the results are not influenced by expectations.
Potential Benefits
The main goals of the study are to:
- Assess the safety and tolerability of ACI-24.060.
- Measure the immune response (production of antibodies) to the medication.
- Evaluate the effect of ACI-24.060 on amyloid levels in the brain and other biomarkers related to Alzheimer's disease.
If successful, this treatment could potentially slow down the progression of Alzheimer's disease in both the general population and in people with Down syndrome.
Safety and Side Effects
As this is a clinical trial, the full range of potential side effects is not yet known. The study will closely monitor participants for any adverse events, which may include:
- Changes in physical and neurological examinations
- Changes in vital signs
- Abnormalities on brain MRI scans
- Changes in blood and urine tests
- Any signs of inflammation in the blood or cerebrospinal fluid (the fluid surrounding the brain and spinal cord)
Participants will also be monitored for any signs of suicidal thoughts or behaviors, as this is a standard precaution in many clinical trials involving brain disorders.
Participation in the Study
To participate in the study, individuals must meet specific criteria. Some key points include:
- For people with Alzheimer's disease: They must have a diagnosis of early (prodromal) Alzheimer's disease and evidence of amyloid buildup in their brain on a PET scan.
- For adults with Down syndrome: They must have a confirmed diagnosis of Down syndrome and evidence of amyloid buildup in their brain on a PET scan.
- Participants must have a study partner who can provide information about their condition and help ensure compliance with the study procedures.
- Certain medical conditions or medications may exclude someone from participating in the study.
If you or a loved one are interested in participating in this clinical trial, it's important to discuss this with your healthcare provider. They can provide more information about the potential risks and benefits, and help determine if this study might be appropriate for your situation.